Title: SiRNA Expression System and Process for Producing Functional Gene Knockdown Cell or the Like Using the Same. Number: 20050048647. Filed: Aug. 13, 2004. PCT Filed: Nov. 28, 2002. Lead Inventor: Kazumari Taira, University of Tokyo.
According to the patent application’s abstract, “the in vivo siRNA expression system according to this invention is a system that intracellularly expresses small-interfering RNAs and comprises antisense and sense code DNAs coding for antisense and sense RNAs targeting any region of a target gene mRNA and one or more promoters that function to express the antisense and sense RNAs from the antisense and sense code DNAs, respectively.
Title: System and Method for Delivering Polynucleotides to the Central Nervous System. Number: 20050048641. Filed: Oct. 12, 2004. Lead Inventor: Keith Hildebrand, Medtronic.
The patent application, its abstract states, covers “methods and apparatuses for delivering RNA polynucleotides to a patient in need thereof.
“Programmable infusion pump systems that include a reservoir housing the RNA polynucleotide are implanted in the patient,” the abstract states. “The RNA polynucleotide is delivered to a target location in the patient via a catheter in communication with the reservoir. The pump system may include one or more sensors that may control rate or timing of delivery of the RNA polynucloetide based on a detected event. The pump system allows for controlled delivery of RNA polynucleotides for the treatment of diseases, disorders, or conditions,” it adds.
Title: RNA Interference-Mediated Inhibition of Intercellular Adhesion Molecule (ICAM) Gene Expression Using Short-Interfering Nucleic Acid. Number: 20050048529. Filed: March 15, 2004. Lead Inventor: James McSwiggen, Sirna Therapeutics.
“This invention relates to compounds, compositions, and methods useful for modulating intercellular adhesion molecule (ICAM) gene expression using short-interfering nucleic acid molecules,” the patent application’s abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ICAM gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the ... invention features small nucleic acid molecules, such as short-interfering nucleic acid, short-interfering RNA, double-stranded RNA, microRNA, and short-hairpin RNA molecules and methods used to modulate the expression of ICAM genes such as ICAM-1, ICAM-2, ICAM-3, ICAM-5, and/or ICAM-6.”
Title: Compositions and Methods for Preparing Short RNA Molecules and Other Nucleic Acids. Number: 20050054847. Filed: July 30, 2004. Lead Inventor: Knut Madden, Invitrogen.
“The invention provides methods of preparing nucleic acids, such as RNA molecules, of a defined size or range of sizes,” the patent application’s abstract states. “The invention provides compositions, methods and kits for use in the production and preparation of small RNA molecules (including without limitation microRNA, siRNA, dsiRNA, and esiRNA) and other nucleic acids of various sizes.”
Title: Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences. Number: 20050054603. Filed: Aug. 18, 2004. Lead Inventor: Chandrasekhar Satishchandran, Wyeth (Nucleonics).
The patent application, its abstract states, covers “a therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell [including] an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, [with] said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein.”
The abstract adds that “the agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; … made in recombinant cultures of microorganisms and isolated therefrom; or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell. In methods of treatment of prophylaxis of virus infections, other pathogenic infections or certain cancers, these compositions are administered in amounts effective to reduce or inhibit the function of the target polynucleotide sequence, which can be of pathogenic origin or produced in response to a tumor or other cancer, among other sources.”
Title: RNA Interference-Mediated Inhibition of Hairless Gene Expression Using Short Interfering Nucleic Acid. Number: 20050054598. Filed: April 23, 2004. Inventor: James McSwiggen, Sirna Therapeutics.
“This invention relates to compounds, compositions, and methods useful for modulating hairless gene expression using short-interfering nucleic acid molecules,” the patent application’s abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of hairless gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short-interfering RNA, double-stranded RNA, microRNA, and short-hairpin RNA molecules and methods used to modulate the expression of hairless genes.”
Title: Automated Laboratory for High-Throughput Biological Assays and RNA Interference. Number: 20050054083. Filed: April 30, 2004. Lead Inventor: Minh Vuong, Aurora Discovery.
“The invention is an automated, multiple-purpose, integrated laboratory system comprising interchangeable modular elements for the construction and measurement of biological assays,” the patent application’s abstract states. “The functions of the modular elements may include multi-well platform handling, chemical reagent or cell management, volumetric transfer of liquids for assay construction, or for recovery of reaction products for analysis, incubation under controlled environmental conditions, measurement of spectrometric signals originating from the assays, processing and analysis of the resulting spectrometric data, and other functions.
“The modular elements are arranged around a number of robotic elements that deliver plates to different modular elements, transfer plates to groups of modules served by a different robotic element, or other actions necessary in plate handling,” the abstract adds. “Liquid transfer to and from multi-well platforms, necessary for assay construction or for the initiation of physiological events in cells, is partitioned among different modules specialized for transferring nanoliter or smaller volume quantities of chemical concentrates, or microliter quantities of assay reagents, cells, media, and other assay constituents.”
The abstract notes that “applications of this invention include the quantitation and analysis of the expression of multiple genes in cells, measurement of multi-gene expression kinetics, analysis of activation or suppression of multiple signal transduction pathways, screening chemical compounds for modulatory effects on multi-gene expression or on signal transduction pathways or on other biochemical networks of cells, or other analytical biological or biochemical assays.”